Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCAT 2023 | Luspatercept and mitapivat for the treatment of patients with beta-thalassemia

Maria Domenica Cappellini • 27 Oct 2023
ASCAT 2023
Non-Malignant Thalassemia
BEYOND ENERGIZE ENERGIZE-T

Maria Domenica Cappellini, MD, University of Milan, Milan, Italy, discusses the approval of luspatercept for the treatment of beta-thalassemia, as well as the ongoing Phase III trials of mitapivat- a pyruvate kinase activator- in both transfusion-dependent and independent patients. This interview was recorded at the 18th Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT) 2023, held in London, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Maria Domenica Cappellini

11:42
Thalassemia highlights at ASH 2023: novel therapies, trial updates & the value of precision medicine
Kevin Kuo et al. • 11 Dec 2023
3:38
Looking to the future in the treatment of beta thalassemia
Maria Domenica Cappellini • 8 Dec 2023
8:38
Treating transfusion dependent and independent beta-thalassemia, and BELIEVE/BEYOND trial updates
Maria Domenica Cappellini • 8 Dec 2023
2:28
Results of the BELIEVE study: luspatercept for the treatment of beta-thalassemia
Maria Domenica Cappellini • 27 Oct 2023

Related Videos

2:01
The MDT in the new era of gene therapy for hemoglobinopathies
Mattia Algeri • 15 Apr 2024
2:38
Treosulfan vs busulfan conditioning in pediatric patients with non-malignant diseases
Rita Beier • 15 Apr 2024
2:18
A global view of transfusion-dependent thalassemia: standard of care, outcomes, and unmet needs
Ali Taher • 15 Apr 2024
1:24
The future of CAR T-reg cells: organ transplantation & autoimmune disease
Zinaida Good • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals